News: Simtuzumab

We provide the latest news and info on Simtuzumab


Drug Discovery & Development
Gilead Releases Phase 2 Pancreatic Cancer Data
Drug Discovery & Development
Gilead Sciences Inc. announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the ...
Stocks Alert: Gilead Sciences, Inc. (NASDAQ:GILD), GT Advanced Technologies ...Techsonian (press release)

all 45 news articles »

Published on Tuesday 28th of October 2014 09:18:59 AM Read more...


Drug Discovery & Development
Reversing Idiopathic Pulmonary Fibrosis
Drug Discovery & Development
Two more interesting drugs, Hogaboam said, are Gilead's Simtuzumab (targeting LoxL2) and Biogen Idec's STX-100 (targeting alpha-beta-6 integrin), both in Phase 2 trial. And high-resolution CT scans will bring earlier diagnosis, key as fibrosis is more ...

and more »

Published on Tuesday 28th of October 2014 09:18:59 AM Read more...

Gilead Sciences, Inc. Stock's Stunning New Opportunity
Motley Fool
The results in blood cancer are heartening, but they're also in stark contrast to another Gilead oncology candidate, simtuzumab, which failed its Phase 2 study for advanced pancreatic cancer this month. Simtuzumab is still in clinical trials for other ...

and more »

Published on Tuesday 28th of October 2014 09:18:59 AM Read more...

The Zacks Analyst Blog Highlights: Auxilium Pharmaceuticals, QLT, Endo ...
PR Newswire (press release)
Gilead (Nasdaq: GILD-Free Report) saw its shares declining slightly on news that its experimental cancer treatment, simtuzumab, failed to achieve the primary endpoint in a mid-stage study. The study was conducted in treatment-naïve advanced pancreatic ...

and more »

Published on Tuesday 28th of October 2014 09:18:59 AM Read more...

Gilead's HIV Tablet Regimen Meets Primary Objective In Two Phase 3 Trials
RTT News
Gilead Sciences, Inc. (GILD: Quote) Wednesday said two final-stage studies have showed that the single tablet regimen containing tenofovir alafenamide for the treatment of HIV-1 infection is non-inferior to Gilead's Stribild, based on the proportion of ...

and more »

Published on Tuesday 28th of October 2014 09:18:59 AM Read more...

Biotech Companies Pushing Sector Higher With Recent Therapeutic ...
SYS-CON Media (press release)
Gilead Sciences Inc. (NASDAQ: GILD) recently announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced ...

and more »

Published on Tuesday 28th of October 2014 09:18:59 AM Read more...

Hot Stocks- Wells Fargo & Co (NYSE:WFC), Groupon Inc(NASDAQ:GRPN), BP ...
Techsonian (press release)
Miami, Florida – Sep 26, 2014 – (Tech Sonian) – Wells Fargo & Co (NYSE:WFC) is pleased to intimated that from Sept. 15 to Oct. 26, Wells Fargo will donate $3 to Operation Smile, an international children's medical charity, for every Wells Fargo ...

and more »

Published on Tuesday 28th of October 2014 09:18:59 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts